The NCI Division of Cancer Prevention funds new research in cancer prevention, detection, screening, interception, and symptom management. We also fund programs to train people for careers in research. Explore current open funding opportunities here and streamline your search by using keyword or type of funding.
Information about the funding opportunity announcements that align with the efforts of the Cancer MoonshotSM can be found here: https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/funding .
Notice of Funding Opportunities
Title
Announcement Number
Activity Code
Clinical Trials Status
Expiration Date
Sort descending
Program Official
HEAL Initiative Notice of Special Interest (NOSI): Development and Validation of Pain-Related Models and Endpoints to Facilitate Non-Addictive Analgesic Discovery
NOT-NS-22-095
06/25/2025
Rachel Altshuler, Ph.D.
Notice of Special Interest (NOSI): Administrative Supplements for Enhancing Recruitment and Retention of Diverse Populations to Cancer Screening, Cancer Prevention and Symptom Management Clinical Trials
NOT-CA-23-071
07/01/2025
Ellen Richmond, M.S., G.N.P.-B.C.
Notice of Special Interest (NOSI): Utilization of Cohorts and Prospective Study Designs for Liquid Biopsy Assay Validation for Early Detection of Cancers
NOT-CA-23-004
07/02/2025
Matthew Young, Ph.D.
NCI Clinical and Translational Exploratory/Developmental Studies
PAR-22-216 (R21 Clinical Trial Optional)
R21
Clinical Trial Optional
07/02/2025
Marjorie Perloff, M.D.
Biology of Bladder Cancer
PAR-22-219 (R21 Clinical Trial Optional)
R21
Clinical Trial Optional
09/08/2025
Biology of Bladder Cancer
PAR-22-218 (R01 Clinical Trial Optional)
R01
Clinical Trial Optional
09/08/2025
Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes
PAR-22-131 (R01 Clinical Trial Optional)
R01
Clinical Trial Optional
09/08/2025
Richard Mazurchuk, Ph.D.
Notice of Special Interest (NOSI): Targeting the Endocannabinoid System for Brain Health and Acute and Chronic Diseases
NOT-DA-22-048
01/08/2026
Sharon Ross, Ph.D., M.P.H.
Assay Validation of High Quality Markers for Clinical Studies in Cancer
PAR-23-313 (UH2/UH3 Clinical Trial Not Allowed)
UH2, UH3
Clinical Trial Not Allowed
10/15/2026
Sudhir Srivastava, Ph.D., M.P.H.
Assay Validation of High Quality Markers for Clinical Studies in Cancer
PAR-23-314 (UH3 Clinical Trials Not Allowed)
UH3
10/15/2026
Sudhir Srivastava, Ph.D., M.P.H.